GLPwatch

[The pharmacological treatment of obesity: past, present and future].

Orv Hetil · 2012

Last updated 2026-05-28

Obesity is a major health issue, and treatments include diet, exercise, behavioral therapy, and medications. While diet and exercise are most effective, they are hard to maintain long-term. Weight-loss drugs can help but often have limited effects and side effects, with weight often returning after stopping the medication. Currently, only orlistat is approved for long-term use, but new drugs like liraglutide (a GLP-1 drug) are being tested.

AI summary of the abstract below.

JournalOrv Hetil, 2012
Citations5
Relative citation ratio0.16
NIH percentile11
Molecules
Conditions studied Obesity

Abstract

Currently, obesity presents one of the biggest health problems. Management strategies for weight reduction in obese individuals include changes in life style such as exercise and diet, behavioral therapy, and pharmacological treatment, and in certain cases surgical intervention. Diet and exercise are best for both prevention and treatment, but both require much discipline and are difficult to maintain. Drug treatment of obesity offer a possible adjunct, but it may only have modest results, limited by side effects; furthermore, the weight lowering effects last only as long as the drug is being taken and, unfortunately, as soon as the administration is stopped, the weight is regained. These strategies should be used in a combination for higher efficacy. Drugs used to induce weight loss have various effects: they increase satiety, reduce the absorption of nutrients or make metabolism faster; but their effect is usually moderate. In the past, several drugs were used in the pharmacological therapy of weight reduction including thyroid hormone, dinitrophenol, amphetamines and their analogues, e.g. fenfluramine, At present, only orlistat is available in the long term treatment (≥ 24 weeks) of obesity as sibutramine and rimonabant were withdrawn form the market. Several new anti-obesity drugs are being tested at present, and liraglutide, a GLP-1 analogue (incretin mimetic), is the most promising one.

Verbatim abstract via PubMed 22370224 ↗